Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119145 | 0.82 | DAO (0.44) | SLC6A2SLC6A4SLC6A3DAOHDAC1 | |
| SCHEMBL29783285 | 0.82 | DAO (0.44) | SLC6A2SLC6A4SLC6A3DAOHDAC1 | |
| SCHEMBL17971122 | 0.81 | ESR1 (0.54) | SLC6A2SLC6A4SLC6A3DAOMMP13 | |
| SCHEMBL79669 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3DAOMMP13 | |
| SCHEMBL12993418 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3DAOMMP13 | |
| SCHEMBL6953517 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3DAOMMP13 | |
| SCHEMBL16646881 | 0.78 | HRH3 (0.46) | SLC6A2SLC6A4SLC6A3DAOMMP13 | |
| SCHEMBL29410646 | 0.78 | HTT (0.47) | DAOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL118519 | 0.78 | HTT (0.47) | DAOCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29559999 | 0.78 | ALDH1A1 (0.40) | HTR2AHTR2CHTR2BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063504-A | Fluoro phenyl phosphate compound, perovskite thin film, perovskite solar cell, preparation method, electric equipment and application | 天合光能股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163029-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| CN-118108676-B | Benzenesulfonamide compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024258728-A2 | EPIDITHIODIKETOPIPERAZINE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3227270-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2024-11-13 | — | — | EP | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-114989164-B | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004031188-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| CN-1441775-A | HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-09-10 | — | — | CN | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | SLC6A2 1874/4885SLC6A4 2249/4885SLC6A3 2388/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A2 3427/4885SLC6A4 3867/4885SLC6A3 2433/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | SLC6A2 3570/4885SLC6A4 4329/4885SLC6A3 3131/4885 |
| US-20250163029-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF | DPYD, PNPO, TYMP | SLC6A2 177/4885SLC6A4 175/4885SLC6A3 215/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A2 3427/4885SLC6A4 3867/4885SLC6A3 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.